Non-small-cell Lung Cancer Clinical Trial
Official title:
Randomized Phase II Study Comparing Stereotactic Body Radiotherapy (SBRT) With Stereotactic Body Proton Therapy (SBPT) for Centrally Located Stage I, Selected Stage II and Recurrent Non-Small Cell Lung Cancer
The goal of this clinical research study is to compare 2 types of radiotherapy, stereotactic body photon radiotherapy (SBRT) and stereotactic body proton radiotherapy (SBPT). Researchers would like to compare the side effects, quality of life, and cancer control.
SBRT and SBPT:
Both SBRT and SBPT affect tumor cells in the same way. SBRT is the more common radiation
technique of the two being studied and has been shown to be effective. However, SBRT may
cause side effects when the tumor is close to normal organs because the photon does not stop
totally after it hits the tumor cells.
SBPT is a type of radiation that uses charged-up particles. This beam of particles can be
targeted like a laser to hit a tumor. When the beam travels through tissue, it starts to slow
down. Doctors can control how deep the radiation particles go, to make sure that enough
radiation hits the tumor being targeted and avoids the surrounding normal organs.
Both forms of radiation will be planned by a radiologist (radiation doctor) who will decide
the dosage of radiation and how it will be given. Radiation technicians will follow the
doctor's instructions to deliver your doses of radiation. Because your body moves during
radiation, both photon and proton beams sometimes may have trouble staying on target. Proton
radiation is more affected by the motion of your body than photon radiation. However, your
doctors will use many methods to reduce motion.
Study Groups/Therapy:
If you are found to be eligible to take part in this study, you will be randomly assigned (as
in a flip of the coin) to 1 of 2 groups. You will have an equal chance of being in either
group.
- If you are in Group 1, you will receive SBRT.
- If you are in Group 2, you will receive SBPT.
You will receive 4 treatments of SBRT or SBPT. During the treatment, you will lie still on a
table for about 30-45 minutes per day in the same position for 4 days in a row.
You will not feel, see, or smell anything during the photon or proton beam delivery.
If you are randomly assigned to SBPT, a member of the radiation therapy staff will place 1-5
tiny metal pellets (called fiducial markers) around the tumor to help the radiation doctor
locate the tumor during the daily proton therapy. The procedure could be done by a
bronchoscopy or using a CT-guided needle placement through the chest wall.
Study Visits:
Once a week during the treatment:
- You will be asked about any side effects you may have had.
- You will have a physical exam.
- Your medical history will be recorded.
Length of Study:
You will finish study treatment after the 4th treatment of SBRT or SBPT. You will no longer
be able to continue the same SBRT or SBPT to the same lesion if the disease gets worse, if
intolerable side effects occur, or if you are unable to follow study directions during the
procedures. However, you can still receive other alternative treatments.
Follow-up Visits:
After the treatment, at 6 weeks, every 3 months (+/-1 month) for 2 years, every 6 months
(+/-1 month) for 3 years, and then once a year for the rest of your life you will have
follow-up. This follow-up schedule is standard of care.
- You will have a physical exam.
- Your medical history will be recorded.
- You will have a chest CT or PET scan to check the status of the disease.
- Blood (about 2 teaspoons) will be drawn for routine tests.
Between 6 weeks and 6 months after treatment and then 1 time a year for 2 years, you will
have a lung function tests.
On the 3rd or 4th follow-up visit and then 1 time a year for 2 years, you will have an ECG. A
SPECT scan may be performed on the 3rd or 4th visit if the doctor thinks it is needed.
Your participation on the study will be over once you have completed the follow-up visits for
2 years. After the 2 years follow up, you will be followed according to the standard of care
as described above. If the follow-up is at another hospital, the information about your
medical history, physical exam, lung function, PET or CT scans will be sent to MD Anderson
for review.
This is an investigational study. SBRT and SBPT are FDA approved for the treatment of lung
cancer.
Up to 100 patients will take part in this study. All will be enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT01136083 -
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Not yet recruiting |
NCT02938546 -
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
|
Phase 3 |